NCT03764722 is a Phase 4 clinical trial of Levosimendan in Systolic Heart Failure, sponsored by Collegium Medicum w Bydgoszczy.

Who is sponsoring NCT03764722?

NCT03764722 is sponsored by Collegium Medicum w Bydgoszczy.

What drugs are being tested in NCT03764722?

Interventions in NCT03764722: Levosimendan.

What condition does NCT03764722 study?

NCT03764722 studies Systolic Heart Failure.

Is NCT03764722 still recruiting?

NCT03764722 is currently status unknown. Last updated 5 December 2018.

Last reviewed 2018-12-05 · How we verify

NCT03764722

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations

Status unknown Phase 4 Last updated 5 December 2018

What this trial tests

Phase 4 trial testing Levosimendan in Systolic Heart Failure in 100 participants. Status unknown.

Timeline

1 August 2018

Primary endpoint
31 December 2021

31 December 2021

Quick facts

Lead sponsor	Collegium Medicum w Bydgoszczy
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 August 2018
Primary completion	31 December 2021
Estimated completion	31 December 2021
Sites	1 location across Poland

Drugs / interventions tested

Levosimendan (LEVOSIMENDAN) — full drug profile →

Conditions studied

Systolic Heart Failure — all drugs for Systolic Heart Failure →

Sponsor

Collegium Medicum w Bydgoszczy — full company profile →

Who can join

Adults 18 to 100, any sex, with Systolic Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Rehospitalizations due to exacerbation of chronic heart failure are an important problem for patients suffering from heart failure. Rehospitalzations lead to worse prognosis, have an impact on the quality of life and have a negative financial impact on the health care system. Currently, studies are being conducted on the efficacy of levosimendan in the prevention of heart failure exacerbations. Patients receive levosimendan at repetitive use and preliminary results suggest a reduction in the incidence of exacerbations of heart failure. Thanks to the clinical trial planned in the Department of Cardiology of the Biziel Hospital with repeatable use of levosimendan, it is possible to determine the benefits of this method of treatment more accurately.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use.
Papp Z, Agostoni P, Alvarez J, Bettex D, et al · · 2020 · cited 47× · PMID 32639325 · DOI 10.1097/fjc.0000000000000859
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use.
Papp Z, Agostoni P, Alvarez J, Bettex D, et al · · 2020 · cited 41× · PMID 32714567 · DOI 10.15420/cfr.2020.03
Evidence and Current Use of Levosimendan in the Treatment of Heart Failure: Filling the Gap.
Conti N, Gatti M, Raschi E, Diemberger I, et al · · 2021 · cited 19× · PMID 34376973 · DOI 10.2147/dddt.s295214

Verify or expand the search:

Other trials of Levosimendan

Trials testing the same drug.

NCT07262723 — Levosimendan in Acute Decompensated Heart Failure · Phase 2, PHASE3 · not yet recruiting
NCT05664191 — Levosimendan as Treatment of Aneurysmal SubArachnoid Haemorrhage · Phase 2 · recruiting
NCT06021587 — Interest of Levosimendan Preconditioning for Cardiac Surgery Under CEC in Heart Failure Patients With Impaired Ejection · unknown
NCT05730907 — Efficacy and Clinical Outcomes of Levosimendan in E-CPR · unknown
NCT05233202 — Levosimendan Versus Placebo Before Tricuspid Valve Surgery in Patients With Right Ventricular Dysfunction · Phase 3 · unknown

Other recruiting trials for Systolic Heart Failure

Currently open trials in the same condition.

NCT05230732 — Neuromodulation of Inflammation and Endothelial Function · NA · recruiting

Other Collegium Medicum w Bydgoszczy trials

Trials by the same sponsor.

NCT07203846 — Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor · Phase 4 · not yet recruiting
NCT07231939 — Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI · recruiting
NCT05905965 — Efficacy of Double vs Standard Empapagliflozin Dose for METabolic syndromE tReatment · Phase 3 · recruiting
NCT05779059 — Prasugrel Or Ticagrelor De-escalation in NSTE-ACS · Phase 3 · unknown
NCT04718025 — Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndro · Phase 3 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03764722 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Collegium Medicum w Bydgoszczy
Last refreshed: 5 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03764722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing